Asahi Kasei Pharma to Sponsor Research for Drug Discovery Research and Tech- nology: Open Innovation 2023

By : Nata Kesuma | Friday, October 14 2022 - 14:35 IWST

Asahi Kasei Pharma
Asahi Kasei Pharma

INDUSTRY.co.id - Düsseldorf, New York and Tokyo, 13 October 2022 – Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world.

The application period begins on 5:00 a.m. GMT at January 5, 2023, and ends at 8:00 a.m. GMT on February 28, 2023.

Asahi Kasei Pharma established its Open Innovation Department in October 2016 with the mission to further strengthen and enhance global licensing and alliance-building activities and has since funded around 5 proposals per year on average with a total of over 20 funded proposals for state-of-the-art pharmaceutical drug developments as well as collected a wealth of creative new ideas.

The Open In- novation team is seeking to fund innovative proposals from researchers around the world for up to US$200,000 per year, per project for this upcoming round in 2023. Asahi Kasei Pharma will then pursue joint research opportunities with the drug discovery researchers together with their parent institutions in hopes to create new innovative drugs for diseases that currently have unmet needs or pioneer new platform technologies for drug discovery.

Asahi Kasei Pharma has demonstrated a successful track record in developing new drugs in the realms of autoimmune, renal, neurological, and bone disease, so the organization can provide the greatest contribution from correlating research areas and subjects.

"Asahi Kasei Pharma believes that nobody should have to give up what they would like to do because of illness," said Osamu Matsuzaki, Primary Executive Officer and Head of R&D and Business Develop- ment at Asahi Kasei Pharma.

“We believe great science comes from working together, and we are excited for the opportunity to accomplish this mission with researchers all over the world.”

Open Innovation works to establish research collaborations related to innovative drug targets and can- didate drug compounds up to the preclinical stage as well as advanced drug discovery technologies. Advancements in exploring a new mechanism of action for treating refractory autoimmune disease is one of the most promising outcomes of the research so far, with many more on the horizon. Asahi Kasei believes that these continued efforts to advance drug discovery and research technology will further contribute to life and living for people around the world.

Outline of the call for proposals Target applicants:

Researchers at universities, research institutes, and enterprises outside Japan (researchers based in Japan should refer to the Japanese website)

Research areas and subjects:

  1. Autoimmune disease - new drug candidates and new drug development technologies
  2. Renal disease - new drug candidates and new drug development technologies
  3. Pain and neurodegenerative disease - new drug candidates and new drug development technol- ogies
  4. Bone disease - new drug candidates

 

  1. Platform technologies for drug discovery - drug formulation, analysis methods and organic syn- thesis

Funding:

Up to US$200,000 per year for each selected proposal

Research period:

1-3 years (milestones will be set for each year, and the content of the research will be reviewed as needed based on the research results)

Submissions will be assessed with respect to their potential as concepts for collaborative research and fostering of research. Further information is available on Asahi Kasei Pharma’s Open Innovation web- site.

About Asahi Kasei Pharma

In accordance with the mission, “to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science,” Asahi Kasei Pharma operates pharmaceutical and diagnostic businesses in the Health Care Sector of the Asahi Kasei Group. Asahi Kasei Pharma has developed numerous innovative drugs in the fields of immunology, neurology, critical care, musculo- skeletal disorders, and other rare diseases, contributing to society by providing highly innovative medi- cations to patients who suffer from diseases with previously unmet needs.

News Comment

Today's Industry

Qatar Airways

Jumat, 03 Februari 2023 - 21:51 WIB

Qatar Airways And Airbus Reach Amicable Settlement In Legal Dispute

Qatar Airways and Airbus are pleased to have reached an amicable and mutually agreeable settlement in relation to their legal dispute over A350 surface degradation and the grounding of A350…

Asia-Pacific Universal Robots

Jumat, 03 Februari 2023 - 19:31 WIB

Universal Robots reports record revenue despite global uncertainty

Universal Robots, the Danish collaborative robot (cobot) company, has reported Q4 revenue of USD 85 million, bringing 2022 annual revenue to USD 326 million, up 5% on 2021. On a constant currency…

PT Jababeka Tbk realized a Rooftop Solar Power Plant (PLTS) and formed the Jababeka Net Zero (JNZ) Forum. The inauguration of PLTS Atap in Jababeka-Cikarang place at the President Executive Club.

Jumat, 03 Februari 2023 - 17:19 WIB

Committed to Being a Net Zero Industrial Estate, Jababeka Inaugurates PLTS Atap and Jababeka Net Zero Forum

After announcing and signing a commitment towards a net zero industrial cluster at the B20 Summit at the G20 Summit series last November 2022, PT Jababeka Tbk realized a Rooftop Solar Power…

Jababeka & SD Darmono Won an Award at PropertyGuru 2022

Jumat, 03 Februari 2023 - 16:00 WIB

Jababeka & SD Darmono Won an Award at PropertyGuru 2022

PT Jababeka Tbk through one of its subsidiaries namely Jababeka Residence, received an award as the Best Mega Township Development at the PropertyGuru Indonesia Property Award 2022, at the Ritz…

Jababeka Net Zero Cluster Announced at World Economic Forum 2023 in Davos- Switzerland

Jumat, 03 Februari 2023 - 15:30 WIB

Jababeka Net Zero Cluster Announced at World Economic Forum 2023 in Davos- Switzerland

PT Jababeka Tbk (Jababeka) is fully committed to helping realize Indonesia’s vision of achieving carbon neutrality by 2060. One of the concrete actions taken by Jababeka is to declare an ambition…